Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. Invivo, prospective study

Osteoarthritis and Cartilage

Volumn 21, Issue 7, 2013, Pages 973-980

  Kyrkos, M J ^a   Papavasiliou, K A ^a   Kenanidis, E ^a   Tsiridis, E ^b   Sayegh, F E ^a   Kapetanos, G A ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Calcitonin; Experimental osteoarthritis; Osteoarthritis

Indexed keywords

PLACEBO; SALCATONIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HISTOLOGY; IN VIVO STUDY; KNEE OSTEOARTHRITIS; MENISCECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CARTILAGE, ARTICULAR; FEMALE; MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS, KNEE; PROSPECTIVE STUDIES; RABBITS; STIFLE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84879461499     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.03.011     Document Type: Article

References (57)

1. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58(1):15-25.
2. Maetzel A., Li L.C., Pencharz J., Tomlinson G., Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004, 63:395-401.
3. Martel-Pelletier J., Wildi L.M., Pelletier J.P. Future therapeutics for osteoarthritis. Bone 2012, 51:297-311.
4. Hunter W. Of the structure and disease of articulating cartilages. 1743. Clin Orthop Relat Res 1995, 3-6.
5. Sondergaard B.C., Catala-Lehnen P., Huebner A.K., Bay-Jensen A.C., Schinke T., Henriksen K., et al. Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthritis Cartilage 2012, 20(2):136-143.
6. Karsdal M.A., Sondergaard B.C., Arnold M., Christiansen C. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis?. Ann N Y Acad Sci 2007, 1117:181-195.
7. El Hajjaji H., Williams J.M., Devogelaer J.P., Lenz M.E., Thonar E.J., Manicourt D.H. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 2004, 12:904-911.
8. Karsdal M.A., Tanko L.B., Riis B.J., Sondergard B.C., Henriksen K., Altman R.D., et al. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?. Osteoarthritis Cartilage 2006 Jul, 14(7):617-624.
9. Chesnut C.H., Azria M., Silverman S., Engelhardt M., Olson M., Mindeholm L. Salmon calcitonin: a review of current andfuture therapeutic indications. Osteoporos Int 2008, 19:479-491.
10. Hulth A., Lindberg L., Telhag H. Experimental osteoarthritis in rabbits. Preliminary report. Acta Orthop Scand 1970, 41:522-530.
11. Colombo C., Butler M., O'Byrne E., Hickman L., Swartzendruber D., Selwyn M., et al. A new model of osteoarthritis in rabbits. I. Development of knee joint pathology following lateral meniscectomy and section of the fibular collateral and sesamoid ligaments. Arthritis Rheum 1983, 26(7):875-886.
12. Kawano T., Miura H., Mawatari T., Moro-Oka T., Nakanishi Y., Higaki H., et al. Mechanical effects of the intraarticular administration of high molecular weight hyaluronic acid plus phospholipid on synovial joint lubrication and prevention of articular cartilage degeneration in experimental osteoarthritis. Arthritis Rheum 2003, 48(7):1923-1929.
13. Chan W.P., Lang P., Stevens M.P., Sack K., Majumdar S., Stoller D.W., et al. Osteoarthritis of the knee: comparison of radiography, CT, and MR imaging to assess extent and severity. AJR Am J Roentgenol 1991, 157(4):799-806.
14. Pritzker K.P., Gay S., Jimenez S.A., Ostergaard K., Pelletier J.P., Revell P.A., et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006, 14(1):13-29.
15. Arden N., Nevitt M.C. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006, 20:3-25.
16. Felson D.T. Clinical practice. Osteoarthritis of the knee. NEngl J Med 2006, 354:841-848.
17. Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289-300.
18. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full invitro analysis. Proc Natl Acad Sci U S A 1999, 96:7563-7568.
19. Dougados M., Nguyen M., Berdah L., Mazieres B., Vignon E., Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001, 44:2539-2547.
20. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
21. Rintelen B., Neumann K., Leeb B.F. Ameta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006, 166:1899-1906.
22. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354(8):795-808.
23. Wang C.T., Lin J., Chang C.J., Lin Y.T., Hou S.M. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. JBone Joint Surg Am 2004, 86-A:538-545.
24. Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7(3):R625-R633.
25. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54(11):3494-3507.
26. Bruyere O., Delferriere D., Roux C., Wark J.D., Spector T., Devogelaer J.P., et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008, 67(3):335-339.
27. Alexandersen P., Karsdal M.A., Byrjalsen I., Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 2011, 14:236-243.
28. Karsdal M.A., Byrjalsen I., Leeming D.J., Christiansen C. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord 2008, 9:153.
29. Tanko L.B., Bagger Y.Z., Alexandersen P., Devogelaer J.P., Reginster J.Y., Chick R., et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004, 19(9):1531-1538.
30. Pun K.K., Chan L.W. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989, 11:205-209.
31. Badurski J., Jeziernicka E., Naruszewicz K., Racewicz A. Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analogue scale (VAS). Pol Tyg Lek 1995, 50:37-40.
32. Sondergaard B.C., Wulf H., Henriksen K., Schaller S., Oestergaard S., Qvist P., et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 2006 Aug, 14(8):759-768.
33. Sondergaard B.C., Catala-Lehnen P., Huebner A.K., Bay-Jensen A.C., Schinke T., Henriksen K., et al. Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthritis Cartilage 2012 Feb, 20(2):136-143.
34. Grauer A., Ziegler R., Raue F. Clinical significance of antibodies against calcitonin. Exp Clin Endocrinol Diabetes 1995, 103:345-351.
35. Muff R., Dambacher M.A., Fischer J.A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporos Int 1991, 1:72-75.
36. Schipper N.G., Romeijn S.G., Verhoef J., Merkus F.W. Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits. Calcif Tissue Int 1994, 54:50-55.
37. Manicourt D.H., Devogelaer J.P., Azria M., Silverman S. Rationale for the potential use of calcitonin in osteoarthritis. JMusculoskelet Neuronal Interact 2005, 5:285-293.
38. Burr D.B., Schaffler M.B. The involvement of subchondral mineralized tissues in osteoarthrosis: quantitative microscopic evidence. Microsc Res Tech 1997, 37:343-357.
39. Peyron J.G. Osteoarthritis. The epidemiologic viewpoint. Clin Orthop Relat Res 1986, 13-19.
40. Baxter E., Fraser J.R., Harris G.S., Martin T.J., Melick R.A. Stimulation of glycosaminoglycan synthesis by thyrocalcitonin preparations. Med J Aust 1968, 1:216-217.
41. Suzuki F., Yoneda T., Shimomura Y. Calcitonin and parathyroid-hormone stimulation of acid mucopolysaccharide synthesis in cultured chondrocytes isolated from growth cartilage. FEBS Lett 1976, 70:155-158.
42. Franchimont P., Bassleer C., Henrotin Y., Gysen P., Bassleer R. Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. JClin Endocrinol Metab 1989, 69:259-266.
43. Badurski J.E., Schwamm W., Popko J., Zimnoch L., Rogowski F., Pawlica J. Chondroprotective action of salmon calcitonin in experimental arthropathies. Calcif Tissue Int 1991, 49:27-34.
44. Kawashima K., Iwata S., Endo H. Selective activation of diaphyseal chondrocytes by parathyroid hormone, calcitonin and N6, O2-dibutyryl adenosine 3',5'-cyclic monophosphoric acid in proteoglycan synthesis of chick embryonic femur cultivated invitro. Endocrinol Jpn 1980, 27:357-361.
45. Kato Y., Nasu N., Takase T., Daikuhara Y., Suzuki F. Aserum-free medium supplemented with multiplication-stimulating activity (MSA) supports both proliferation and differentiation ofchondrocytes in primary culture. Exp Cell Res 1980, 125:167-174.
46. Dieppe P., Watt I. Crystal deposition in osteoarthritis: an opportunistic event?. Clin Rheum Dis 1985, 11:367-392.
47. Gowen M., Mundy G.R. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption invitro. JImmunol 1986, 136:2478-2482.
48. Jilka R.L., Hamilton J.W. Evidence for two pathways for stimulation of collagenolysis in bone. Calcif Tissue Int 1985, 37:300-306.
49. Papaioannou N.A., Triantafillopoulos I.K., Khaldi L., Krallis N., Galanos A., Lyritis G.P. Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study. Osteoarthritis Cartilage 2007, 15:386-395.
50. Manicourt D.H., Altman R.D., Williams J.M., Devogelaer J.P., Druetz-Van Egeren A., Lenz M.E., et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 1999, 42(6):1159-1167.
51. Behets C., Williams J.M., Chappard D., Devogelaer J.P., Manicourt D.H. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. JBone Miner Res 2004, 19:1821-1826.
52. Nielsen R.H., Bay-Jensen A.C., Byrjalsen I., Karsdal M.A. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage 2011, 19:466-473.
53. Segovia-Silvestre T., Bonnefond C., Sondergaard B.C., Christensen T., Karsdal M.A., Bay-Jensen A.C. Identification of the calcitonin receptor in osteoarthritic chondrocytes. BMC Res Notes 2011, 4:407.
54. Lin Z., Pavlos N.J., Cake M.A., Wood D.J., Xu J., Zheng M.H. Evidence that human cartilage and chondrocytes do not express calcitonin receptor. Osteoarthritis Cartilage 2008, 16:450-457.
55. Karsdal M.A., Byrjalsen I., Henriksen K., Riis B.J., Lau E.M., Arnold M., et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010 Feb, 18(2):150-159.
56. Bagger Y.Z., Tankó L.B., Alexandersen P., Karsdal M.A., Olson M., Mindeholm L., et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005 Sep, 37(3):425-430.
57. Karsdal M.A., Henriksen K., Bay-Jensen A.C., Molloy B., Arnold M., John M.R., et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol 2011 Apr, 51(4):460-471.